Simultaneous administration of ibrutinib and anti-CD19 CAR T cells was well tolerated by CLL patients and led to higher rates of minimal residual disease (MRD)-negative response [97]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.